GREAT WEST LIFE ASSURANCE CO /CAN/ - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.

Quarter-by-quarter ownership
GREAT WEST LIFE ASSURANCE CO /CAN/ ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$99
+70.7%
3,615
+112.5%
0.00%
Q2 2023$58
-4.9%
1,7010.0%0.00%
Q1 2023$61
-34.4%
1,701
-17.8%
0.00%
Q4 2022$93
-99.8%
2,0700.0%0.00%
Q3 2022$58,000
+3.6%
2,0700.0%0.00%
Q2 2022$56,000
-25.3%
2,0700.0%0.00%
Q1 2022$75,000
-6.2%
2,0700.0%0.00%
Q4 2021$80,000
-29.2%
2,0700.0%0.00%
Q3 2021$113,000
+32.9%
2,070
-18.8%
0.00%
Q2 2021$85,000
+63.5%
2,5500.0%0.00%
Q1 2021$52,000
+15.6%
2,5500.0%0.00%
Q4 2020$45,0002,5500.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2023
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders